Moderna (NASDAQ:MRNA) Stock Jumps 3.4% – Time to Buy?

Posted by Francis Steltz on Nov 5th, 2026

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) were up 3.4% on Tuesday. The company traded as high as $235.50 and last traded at $228.44. Approximately 9,477,924 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 12,619,756 shares. The stock had previously closed at $220.83.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Health Canada authorized Moderna’s mRNA seasonal influenza vaccine and its combined influenza/COVID-19 vaccine for adults 50 and older, making Canada the first country to authorize both products. The approvals expand potential commercial opportunities, though sales and uptake remain to be seen. Health Canada authorizes Moderna’s vaccines
Positive Sentiment: Moderna’s investigational multiple-myeloma therapy mRNA-2808 generated four confirmed responses among 11 heavily pretreated patients in early data. The results are preliminary, but helped fuel optimism about the company’s cancer platform; fuller data are scheduled for presentation at a December medical meeting. Early multiple-myeloma data
Positive Sentiment: The WHO’s technical advisory group recommended advancing Moderna’s Bundibugyo Ebola vaccine candidate to a Phase 2/3 efficacy study in the Democratic Republic of the Congo, a positive development for its pipeline. Ebola vaccine advances toward Phase 2/3
Neutral Sentiment: Investors are looking to Friday’s earnings report for updates on revenue, cash use, and the company’s ability to fund its pipeline. The results could be an important test after a steep rally. Q3 earnings preview
Negative Sentiment: U.S. judges pressed Moderna on its defense in a COVID-19 vaccine patent dispute that could involve billions of dollars, raising uncertainty about potential legal exposure. Moderna pressed on patent defense
Negative Sentiment: Some commentary argues the stock’s valuation has run ahead of near-term revenue prospects, citing ongoing cash burn and commercial hurdles for pipeline products. That risk may weigh more heavily if earnings do not support the rally. Moderna earnings and valuation analysis

Analyst Ratings Changes

Several analysts have recently weighed in on MRNA shares. Bank of America lifted their target price on Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Loop Capital set a $135.00 price target on shares of Moderna in a report on Wednesday, August 19th. Argus raised shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research note on Friday, August 28th. Barclays raised their price target on shares of Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, August 24th. Finally, Evercore lifted their price objective on shares of Moderna from $50.00 to $80.00 in a report on Thursday, October 8th. Six equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and a consensus target price of $107.10.

Get Our Latest Research Report on Moderna

Moderna Trading Down 6.5%

The firm has a 50 day moving average of $189.62 and a 200-day moving average of $90.46. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Insider Buying and Selling at Moderna

In other news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,251 shares of company stock valued at $33,875,904 in the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently made changes to their positions in MRNA. BlackRock Inc. acquired a new position in shares of Moderna in the second quarter valued at about $2,142,877,000. Theleme Partners LLP purchased a new position in shares of Moderna in the second quarter worth about $564,272,000. Merck & Co. Inc. acquired a new stake in shares of Moderna during the second quarter worth about $161,642,545. Bamco Inc. NY acquired a new stake in shares of Moderna during the second quarter worth about $139,317,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Moderna during the second quarter worth about $119,168,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

(Get Free Report)

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.